Programmed Death-Ligand (PD-L1), Epidermal Growth Factor (EGF), Relaxin, and Matrix Metalloproteinase-3 (MMP3): Potential Biomarkers of Malignancy in Canine Mammary Neoplasia

Int J Mol Sci. 2024 Jan 18;25(2):1170. doi: 10.3390/ijms25021170.

Abstract

Gene expression has been suggested as a putative tool for prognosis and diagnosis in canine mammary neoplasia (CMNs). In the present study, 58 formalin-fixed paraffin-embedded (FFPE) paraffined canine mammary neoplasias from 27 different bitches were included. Thirty-seven tumours were classified as benign, whereas thirty-one were classified as different types of canine carcinoma. In addition, mammary samples from three healthy bitches were also included. The gene expression for vascular endothelial growth factor-α (VEGFα), CD20, progesterone receptor (PGR), hyaluronidase-1 (HYAL-1), programmed death-ligand 1 (PD-L1), epidermal growth factor (EGF), relaxin (RLN2), and matrix metalloproteinase-3 (MMP3) was assessed through RT-qPCR. All the assessed genes yielded a higher expression in neoplastic mammary tissue than in healthy tissue. All the evaluated genes were overexpressed in neoplastic mammary tissue, suggesting a role in the process of tumorigenesis. Moreover, PD-L1, EGF, relaxin, and MMP3 were significantly overexpressed in malignant CMNs compared to benign CMNs, suggesting they may be useful as malignancy biomarkers.

Keywords: canine mammary neoplasia; epidermal growth factor; gene expression; malignancy biomarkers; matrix metalloprotease-3; programmed death-ligand 1; relaxin.

MeSH terms

  • Animals
  • B7-H1 Antigen
  • Biomarkers
  • Dogs
  • Epidermal Growth Factor / genetics
  • Ligands
  • Mammary Neoplasms, Animal* / genetics
  • Matrix Metalloproteinase 3 / genetics
  • Relaxin* / genetics
  • Vascular Endothelial Growth Factor A

Substances

  • Epidermal Growth Factor
  • Relaxin
  • Matrix Metalloproteinase 3
  • B7-H1 Antigen
  • Ligands
  • Vascular Endothelial Growth Factor A
  • Biomarkers

Grants and funding

M.T. is supported by the Plan Nacional de Investigación (reference PID 2020-113221RB-I00), and a Ramón y Cajal contract (reference RYC 2019-026841-I).